An Open-Label, Multicenter, Phase I/II Clinical Trial to Identify the Modufolin Dose With Most Favorable Safety Prospect and Confirmed Ability to Mitigate High-Dose Methotrexate Induced Toxicity During Treatment of Osteosarcoma Patients

Trial Profile

An Open-Label, Multicenter, Phase I/II Clinical Trial to Identify the Modufolin Dose With Most Favorable Safety Prospect and Confirmed Ability to Mitigate High-Dose Methotrexate Induced Toxicity During Treatment of Osteosarcoma Patients

Completed
Phase of Trial: Phase I/II

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs Folitixorin (Primary) ; Folinic acid; Methotrexate
  • Indications Folic acid deficiency; Osteosarcoma
  • Focus Adverse reactions
  • Sponsors Isofol Medical
  • Most Recent Events

    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress.
    • 11 Sep 2017 Results published in the Isofol Medical Media Release
    • 11 Sep 2017 Results published in the Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top